Axillary Management of Stage II/III Breast Cancer in Patients Treated With Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative)

Journal of the American College of Surgeons - Netherlands
doi 10.1016/j.jamcollsurg.2016.12.036
Full Text
Abstract

Available in full text

Categories
Surgery
Date
Authors
Publisher

Elsevier BV

Related search

Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-Per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2015English

Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2015English

Positive Response to Neoadjuvant Cyclophosphamide and Doxorubicin in Topoisomerase II Nonamplified/Her2/Neu Negative/Polysomy 17 Absent Breast Cancer Patients

Cancer Management and Research
Oncology
2010English

Long-Term Prognostic and Predictive Factors in 107 Stage II/III Breast Cancer Patients Treated With Anthracycline-Based Neoadjuvant Chemotherapy

British Journal of Cancer
Cancer ResearchOncology
1997English

Neoadjuvant Therapy With Cisplatin in BRCA1-positive Breast Cancer Patients

Hereditary Cancer in Clinical Practice
OncologyGenetics
2011English

Clinical Outcomes and Prognostic Factors in Locally Advanced Breast Cancer Patients With Estrogen Receptor-Positive, HER2-Negative Subtype Treated With Neoadjuvant Chemotherapy and Surgery Followed by Postmastectomy Radiation Therapy

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2019English

Neoadjuvant Systemic Therapy in Breast Cancer

2012English

CD44v9 as a Poor Prognostic Factor of Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy

Breast Cancer
Nuclear MedicineRadiologyPharmacologyOncologyImagingMedicine
2018English

Phase II Study of Pembrolizumab and Capecitabine for Triple Negative and Hormone Receptor-Positive, HER2−negative Endocrine-Refractory Metastatic Breast Cancer

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy